Peptide LibrarySomatrogon dosage in published studies and labels
These are the doses used for Somatrogon in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Somatrogon has an FDA-approved human dosage as Ngenla, for children aged 3 years and older with growth failure due to inadequate secretion of growth hormone. The label dose is 0.66 mg/kg of actual body weight once a week by subcutaneous injection, individualised by growth response. The US label covers no adult use.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.66 mg/kg once weekly (weight-based, children) |
| Route | Subcutaneous |
| Frequency | Once weekly, on the same day each week |
| Duration studied | Continuous while treating growth failure |
| Titration | No escalation schedule: the label dose is 0.66 mg/kg once weekly, individualised by growth response. The dosing day can move if at least 3 days separate two doses. |
| Half-life | Effective half-life of about 37.7 hours in children with growth hormone deficiency (population estimate); present in the circulation for about 8 days after the last dose (Ngenla label) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Ngenla, paediatric growth hormone deficiencyFDA-approved label · FDA prescribing information | Children aged 3 years and older with growth failure due to inadequate secretion of endogenous growth hormone | 0.66 mg/kg of actual body weight | Subcutaneous, abdomen, thighs, buttocks or upper arms, rotating the site weekly | Once weekly | Individualised by growth response | In the label's 52-week phase 3 study (224 treatment-naive prepubertal children), annualised height velocity was 10.1 cm/year with Ngenla and 9.8 cm/year with daily somatropin 0.034 mg/kg/day | NGENLA (somatrogon-ghla) injection — FDA prescribing information, DailyMed |
Where sources disagree
- Ngenla is dosed once a week by body weight. Its 0.66 mg/kg weekly dose does not convert to daily somatropin: in the label's study the daily somatropin comparison arm received 0.034 mg/kg/day.
- The US label is for children aged 3 years and older with growth hormone deficiency. It is not indicated for children with growth failure due to genetically confirmed Prader-Willi syndrome, and it covers no adult, anti-ageing or performance use.
- Somatrogon is growth hormone joined to peptides from the beta chain of hCG, and it comes only in prefilled pens (24 mg and 60 mg) that deliver doses in 0.2 mg or 0.5 mg steps. It is not the same product as daily somatropin or the other once-weekly growth hormones (somapacitan, lonapegsomatropin), whose labels set their own doses.